HIV Infections: all 4,342 studies

Page 36 of 44. Open to participants first (242), then studies with results posted, then the rest; newest registration first within each.

• Safety of and Immune Response to Polyvalent HIV-1 Vaccine in HIV Uninfected AdultsStatus unknownNCT00061243Phase 1
• Pilot Study of High-Concentration Capsaicin Patches in the Treatment of Painful HIV-Associated NeuropathyStatus unknownNCT00061152Phase 2
• Safety and Efficacy of BAY 50-4798 in Patients With HIV InfectionCompletedNCT00059462Phase 1/2
• Alternative Dosing Strategy for Anti-HIV DrugsCompletedNCT00059384Phase 4
• Male Circumcision and HIV Rates in KenyaCompletedNCT00059371Phase 3
• Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected PatientsCompletedNCT00058734Phase 1
• Curb, Alter, Lower, or Manage Stress in HIV: CALMS-HIVCompletedNCT00057538Phase 2
• Tuberculosis in HIV Infected Patients in UgandaCompletedNCT00057421Phase 2
• Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIVCompletedNCT00056797Phase 2
• HIV Vaccine Designed for HIV Infected Adults Taking Anti-HIV DrugsCompletedNCT00056758Phase 1
• Determining an Effective Site (Groin Versus Arm) for Giving HIV VaccinesCompletedNCT00056745Phase 1
• Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected PatientsCompletedNCT00056641Phase 2
• Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected PatientsCompletedNCT00055185Phase 2
• Treatment of Acute HIV Infection to Preserve Immune FunctionCompletedNCT00055094
• Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected AdultsCompletedNCT00054860Phase 1
• Differences in Blood Levels of Nevirapine in HIV-infected Patients in Uganda and the United StatesCompletedNCT00054743Phase 4
• A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior TherapyCompletedNCT00053638Phase 3
• Handheld Computers to Improve Adherence to Anti-HIV Drug RegimensCompletedNCT00053443Phase 2
• Using the Drug Thalidomide to Stimulate T Cells in HIV-Infected PeopleCompletedNCT00053430Phase 2
• Immunologic Control of Drug Resistant HIVStatus unknownNCT00053404
• Investigational Vaccine for the Prevention of Disseminated Tuberculosis in HIV Infected PeopleCompletedNCT00052195Phase 2/3
• Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Infected PatientsCompletedNCT00052182Phase 1
• Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With Antiretroviral RegimensCompletedNCT00052117Phase 2
• Development of a New HIV VaccineCompletedNCT00051922Phase 1
• Capravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected Patients Who Failed an Initial NNRTI Containing RegimenCompletedNCT00051844Phase 2
• Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive AdultsCompletedNCT00051831Not applicable
• Immune and Viral Outcomes of HIV-1 Therapy InterruptionCompletedNCT00051818Phase 1
• Promoting Adherence to Anti-HIV Drug RegimensCompletedNCT00051805Not applicable
• Computer-Assisted Adherence Program for Patients Taking Anti-HIV DrugsTerminatedNCT00051766Not applicable
• Screening HIV-Infected Patients for Vaccine StudiesCompletedNCT00051519
• Evaluation of the Safety of and Immune Response to an HIV Vaccine in Healthy AdultsCompletedNCT00051454Phase 1/2
• Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIVWithdrawnNCT00051090Not applicable
• Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)WithdrawnNCT00051077Phase 2
• Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV DrugsCompletedNCT00050921Not applicable
• Blood Vessel Function in HIV-Infected Patients Taking Anti-HIV DrugsCompletedNCT00050908
• Studies of Influenza Vaccine and Tetanus-Pneumococcal Vaccine in HIV-infected Patients Receiving Interleukin-2CompletedNCT00050726Phase 2
• Discontinuation of Antiretroviral Therapy in Patients With Asymptomatic HIV InfectionCompletedNCT00050284
• Influence of the MDR1 Genotype on Blood Levels of Indinavir and Saquinavir in Healthy VolunteersCompletedNCT00050180Phase 4
• Effects of Therapeutic HIV Vaccination on Control of HIV After Discontinuation of Anti-HIV DrugsCompletedNCT00050063
• HIV Prevention Preparedness StudyCompletedNCT00048282
• A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102Status unknownNCT00048217Phase 1/2
• Rapid HIV Tests for Women Late in Pregnancy and During LaborTerminatedNCT00046436
• Atazanavir for HIV Infected Individuals: An Early Access ProgramNo longer availableNCT00046345
• A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected PatientsCompletedNCT00046332Phase 2
• Multicenter AIDS Cohort Study (MACS)Status unknownNCT00046280
• A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced PatientsCompletedNCT00046176Phase 3
• Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug ResistanceCompletedNCT00046033Phase 2
• Hormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal WomenTerminatedNCT00044837Phase 1
• New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected SubjectsCompletedNCT00044577Phase 3
• Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve SubjectsCompletedNCT00043966Phase 3
• Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected SubjectsCompletedNCT00043953Phase 2
• Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIRCompletedNCT00043888Phase 3
• HIV Expression in Patients With Low Viral Load on Highly Active Antiretroviral Therapy (HAART)CompletedNCT00043641
• Safety of an HIV DNA Vaccine Given to HIV Uninfected AdultsCompletedNCT00043511Phase 1
• A Study of HIV Levels During Pregnancy and After ChildbirthCompletedNCT00041964
• Using Drug Levels in the Blood to Guide Therapy in HIV Infected Patients Taking a Protease InhibitorCompletedNCT00041769Phase 3
• A 14-Day Study of Racivir When Used in Combination in HIV-Infected MalesCompletedNCT00040300Phase 1
• A Study of DPC 817 in HIV-Infected MalesCompletedNCT00040274Phase 1
• Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.TerminatedNCT00040157Phase 2
• Endothelial Dysfunction as a Risk Factor in HIV StudyCompletedNCT00039663Phase 1
• A Study of Peer Education to Prevent HIV Transmission Among Injection Drug Users and Their HIV Risk ContactsCompletedNCT00038688Phase 3
• A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase InhibitorsCompletedNCT00038636Phase 3
• Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAARTCompletedNCT00038532Phase 2
• Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease InhibitorCompletedNCT00038519Phase 2/3
• Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic FailureCompletedNCT00038506Phase 4
• Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected InfantsCompletedNCT00038480Phase 1
• A Study of DAPD Alone Versus DAPD Plus MMF for Treatment of HIV InfectionCompletedNCT00038272Phase 2
• Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug TherapyCompletedNCT00038259Not applicable
• Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected PatientsCompletedNCT00038220Phase 2
• A Study to See if Certain Antioxidants and Vitamins Will Keep Lactate Levels Down in Patients Taking Anti-HIV DrugsWithdrawnNCT00037063Not applicable
• A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive PatientsCompletedNCT00036634Phase 1/2
• Effects of Changing HIV Therapy at Lower Versus Higher Viral LoadsCompletedNCT00036465Phase 2
• A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct ObservationCompletedNCT00036452Phase 2
• The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAARTCompletedNCT00035893Phase 2
• Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAARTTerminatedNCT00035581Phase 2
• Phase III PEG-Intron in HIV-infected Patients (Study P00738)CompletedNCT00035360Phase 3
• Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected IndividualsCompletedNCT00034866Phase 2
• Study of Anti-HIV Therapy IntensificationCompletedNCT00034086Not applicable
• Treatment of Depression With Massage in HIVCompletedNCT00033852Phase 2
• Immune Restoration by Lipoic Acid in AIDSCompletedNCT00033176Phase 2
• The Use of Reiki for Patients With Advanced AIDSCompletedNCT00032721Phase 2
• Therapeutic Drug Monitoring and Viral Resistance Testing in the Treatment of HIV-Infected ChildrenCompletedNCT00032669Phase 1
• Consent for Use of Stored Patient Specimens for Future TestingActive, not recruitingNCT00031408
• Screening Protocol for HIV Vaccine StudiesCompletedNCT00031304
• The Effectiveness of Human Antibodies in Influencing an AIDS-Like Disease in MonkeysCompletedNCT00031109Not applicable
• Increasing HAART-Induced Immune Restoration With CyclosporineCompletedNCT00031070Phase 2
• Adding New Drugs for HIV Infected Patients Failing Current TherapyCompletedNCT00031044Phase 1/2
• A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness TrialsCompletedNCT00029913
• A Study to Prepare for Future HIV Vaccine StudiesCompletedNCT00029744
• A Study to Demonstrate That Anti-HIV Drug Therapy Can be Stopped Without Causing Viral Resistance, and to Characterize Drug Elimination From the BodyCompletedNCT00029341Phase 2
• Alternative Stress Management Approaches in HIV DiseaseCompletedNCT00029237Phase 3
• Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected PeopleCompletedNCT00028366Not applicable
• Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive CareCompletedNCT00028327Phase 3
• Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)CompletedNCT00028301Phase 3
• Prenatal and Postnatal Studies of Interventions for Prevention of Mother-To-Child TransmissionCompletedNCT00028145
• Safety and Acceptability of the Anti-Microbe Vaginal Gel, PMPA GelCompletedNCT00028132Phase 1
• HIV Incidence and Participation Retention in Pune, IndiaCompletedNCT00028119
• A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease InhibitorTerminatedNCT00028067Phase 3
• Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected VolunteersCompletedNCT00027482
• An Investigational Combination Vaccine Given to People Who Are Not Infected With HIVCompletedNCT00027365Phase 1

← HIV Infections overview